NSAID Safety with COVID-19 Infection

Save

NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.

RheumNow Podcast – Falling or Falling in Love?

Save

Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.

Drug Monitoring Ineffective with Infliximab Treatment

Save

The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not.

Results Disappoint for Fecal Transplant in Arthritis

Save

Fecal microbiota transplantation (FMT) showed disappointing results among patients with active psoriatic arthritis, a small randomized trial found.

RheumNow Podcast – Uppers and Downers

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Predictors of Methotrexate Toxicity

Save

A metanalysis showed that while adverse events (AEs) are common when methotrexate is used in rheumatoid arthritis or inflammatory arthritis patients, serious AEs ranged from 2.1 to 9.5% and drug discontinuations ranged from 6.7% to 15.5%, mostly due to gastrointestinal events. 

Psoriatic Pregnancies Pose Risks to the Mother, Not Child

Save

A metanalysis of pregnancy outcomes in women with psoriasis and psoriatic arthritis finds an excess risk of adverse maternal events, but not adverse neonatal events.

This systematic review included 16 studies meeting inclusion criteria. 

Dual IL-17 Targeting is Effective but has More Candidiasis

Save

Bimekizumab (BIM) is a monoclonal antibody that targets both interleukin-17A and interleukin-17F, which as a biologic target has worked well in the management of psoriatic disease. The current issue of the NEJM has two reports wherein BIM was shown to be more effective than secukinumab and adalimumab in treating patients with moderate-to-severe plaque psoriasis; however, safety concerns arise. 

RheumNow Podcast – Coconspirators: RA and Lung Disease

Save

Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.

Diagnostic Delay in Spondyloarthritis

Save

Literature review and metanalysis of many studies suggests that significant delay to diagnosis in axial spondyloarthritis (axSpA) exist, are longer than other rheumatic diseases and have not changed over time.

Increased Methotrexate Liver Disease in Psoriasis

Save

A Danish cohort study examined the risk of methotrexate related liver disease risk in patients with psoriasis (PsO)and psoriatic arthritis (PsA), and found that compared to rheumatoid arthritis (RA), psoriatic patients had up to a 3 fold higher risk of liver disease. 

BSRBR: Demyelinating Disease Following Anti-TNFα Therapy

Save

Analysis of patients receiving anti–tumor necrosis factor α (TNFi) therapy in the British Society for Rheumatology Biologics Register (BSRBR) shows that the risk of demyelination is rare but is marginally incrased by taking TNFi therapy. 

IL-23 Targeting for Enthesitis in Psoriatic Arthritis

Save

Treatment with guselkumab (Tremfya) was effective in resolving enthesitis among patients with psoriatic arthritis (PsA), a post-hoc analysis of two phase III trials found.

Low Risk of Malignancy with Secukinumab

Save

Analysis of ongoing safety from the secukinumab (SEC) drug development program shows a low risk for malignancy in SEC patients treated for up to five years for either psoriasis, psoriatic arthritis (PsA) or ankylosing spondylitis (AS).

DMARD Dropouts During COVID-19

Save

A full year from the onset of the SARS-COV-2 pandemic, rheumatologists are still seeing the consequences of COVID, with many patients avoiding usual care, follow-up visits, routine lab testing and with many self-stopping their antirheumatic meds, because it seemed like the right thing to do.

RheumNow Podcast – Mistakes with Steroids

Save

Dr Jack Cush gives his spin on this week's RheumNews and Rheum Research from RheumNow.com.

Rheumatology Care Derailed by COVID-19

Save

A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.

RheumNow Podcast – Upadacitinib Wins in PsA (4.2.2021)

Save

Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers.

Upadacitinib Clinical Efficacy in Psoriatic Arthritis

Save

McInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

Save

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.